Analyst Price Target is $10.17
▲ +308.30% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Solid Biosciences in the last 3 months. The average price target is $10.17, with a high forecast of $17.00 and a low forecast of $6.00. The average price target represents a 308.30% upside from the last price of $2.49.
Current Consensus is
The current consensus among 6 contributing investment analysts is to buy stock in Solid Biosciences. This rating has held steady since May 2020, when it changed from a Hold consensus rating.
Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy (DMD). It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.